Table 4. Anti-SE36 antibody titers pre-vaccination (baseline) and 21 days post-second vaccination in Stage1.

				ELISA titer		Change from
				Geometric mean [95% CI]		baseline
Seroconversion	Gender	Vaccine	Statistic	Baseline	21 days after 2nd vaccination	p value
Negative	Male	BKSE1.0	FAS n	9	9	FAS:
			GM	35.90 [22.73; 56.70]	59.05 [44.84; 77.77]	Within BKSE1.0 = 0.004
			PPS n	7	7
			GM	34.26 [18.33; 64.03]	56.02 [40.35; 77.77]	Between BKSE1.0 vs.
		Saline	FAS n	5	5	Saline = 0.02
			GM	24.35 [13.67; 43.35]	29.79 [9.00; 98.62]
			PPS n	4	4	PPS:
			GM	21.07 [11.41; 38.91]	19.66 [12.28; 31.47]	Within BKSE1.0 = 0.04
	Female	BKSE1.0	FAS n	9	9
			GM	22.04 [12.08; 40.19]	34.48 [21.66; 54.87]	Between BKSE1.0 vs.
			PPS n	6	6	Saline = 0.014
			GM	29.41 [13.13; 65.85]	44.45 [26.84; 73.61]
		Saline	FAS/PPS n	5	4
			GM	36.80 [8.75; 154.74]	26.32 [4.46; 155.30]
Positive	Male	BKSE1.0	FAS n	9	9	FAS:
			GM	465.40 [207.70;1042.87]	403.87 [205.73; 792.81]	Within BKSE1.0 = 0.39
			PPS n	6	6
			GM	511.44 [160.85;1626.15]	418.59 [170.79;1025.91]	Between BKSE1.0 vs.
		Saline	FAS/PPS n	5	5	Saline = 0.47
			GM	237.52 [142.75; 395.19]	333.08 [145.9; 760.40]
	Female	BKSE1.0	FAS n	9	9	PPS:
			GM	469.32 [260.81; 844.52]	496.68 [254.68; 968.65]	Within BKSE1.0 = 0.11
			PPS n	7	7
			GM	521.47 [257.93;1054.29]	460.62 [206.87;1025.62]	Between BKSE1.0 vs.
		Saline	FAS/PPS n	5	5	Saline = 0.19
			GM	495.74 [114.01; 2155.55]	340.44 [67.66; 1713.09]

Statistic is presented either as immunogenicity full analysis set (FAS) or per-protocol set (PPS); n = number of subjects; GM = geometric mean; CI = confidence interval of geometric mean; For additional information on PPS, refer to Text S1. p values are based on analysis within treatment group (Signed Rank), and between treatment groups (Wilcoxon Rank Sums).